SAB Biotherapeutics Net Income
| SABS Stock | USD 4.17 0.19 4.77% |
As of the 10th of February, SAB Biotherapeutics owns the Standard Deviation of 3.91, market risk adjusted performance of (2.83), and Semi Deviation of 3.31. In respect to fundamental indicators, the technical analysis model makes it possible for you to check possible technical drivers of SAB Biotherapeutics, as well as the relationship between them. Please validate SAB Biotherapeutics variance, as well as the relationship between the value at risk and skewness to decide if SAB Biotherapeutics is priced fairly, providing market reflects its prevailing price of 4.17 per share. Given that SAB Biotherapeutics has jensen alpha of 0.4571, we advise you to double-check SAB Biotherapeutics's latest market performance to make sure the company can sustain itself in the future.
SAB Biotherapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.206 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -30.7 M | -29.2 M | |
| Net Loss | -16.9 M | -16 M | |
| Net Loss | -30.7 M | -29.2 M | |
| Net Loss | (4.23) | (4.45) | |
| Net Income Per E B T | 0.90 | 0.80 |
SAB | Net Income | Build AI portfolio with SAB Stock |
The evolution of Net Income for SAB Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how SAB Biotherapeutics compares to historical norms and industry peers.
Latest SAB Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of SAB Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in SAB Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of SAB Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is SAB Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (34.11 M) | 10 Years Trend |
|
Net Income |
| Timeline |
SAB Net Income Regression Statistics
| Arithmetic Mean | (14,222,478) | |
| Geometric Mean | 13,946,869 | |
| Coefficient Of Variation | (98.73) | |
| Mean Deviation | 10,200,619 | |
| Median | (8,986,000) | |
| Standard Deviation | 14,041,532 | |
| Sample Variance | 197.2T | |
| Range | 62.3M | |
| R-Value | (0.56) | |
| Mean Square Error | 144.3T | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | (1,557,350) | |
| Total Sum of Squares | 3154.6T |
SAB Net Income History
Other Fundumenentals of SAB Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
SAB Biotherapeutics Net Income component correlations
SAB Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Net Income. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will SAB introduce new products? Factors like these will boost the valuation of SAB Biotherapeutics. If investors know SAB will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about SAB Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share (1.56) | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets |
SAB Biotherapeutics's market price often diverges from its book value, the accounting figure shown on SAB's balance sheet. Smart investors calculate SAB Biotherapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since SAB Biotherapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between SAB Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SAB Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SAB Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
SAB Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to SAB Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of SAB Biotherapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in SAB Biotherapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding SAB Biotherapeutics or generate 0.0% return on investment in SAB Biotherapeutics over 90 days. SAB Biotherapeutics is related to or competes with Verrica Pharmaceuticals, Pluri, NextCure, Q32 Bio, AN2 Therapeutics, Jasper Therapeutics, and Evaxion Biotech. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies bas... More
SAB Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure SAB Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess SAB Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.78 | |||
| Information Ratio | 0.0908 | |||
| Maximum Drawdown | 22.52 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 6.13 |
SAB Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for SAB Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as SAB Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use SAB Biotherapeutics historical prices to predict the future SAB Biotherapeutics' volatility.| Risk Adjusted Performance | 0.101 | |||
| Jensen Alpha | 0.4571 | |||
| Total Risk Alpha | 0.0129 | |||
| Sortino Ratio | 0.0939 | |||
| Treynor Ratio | (2.84) |
SAB Biotherapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.101 | |||
| Market Risk Adjusted Performance | (2.83) | |||
| Mean Deviation | 2.9 | |||
| Semi Deviation | 3.31 | |||
| Downside Deviation | 3.78 | |||
| Coefficient Of Variation | 862.08 | |||
| Standard Deviation | 3.91 | |||
| Variance | 15.27 | |||
| Information Ratio | 0.0908 | |||
| Jensen Alpha | 0.4571 | |||
| Total Risk Alpha | 0.0129 | |||
| Sortino Ratio | 0.0939 | |||
| Treynor Ratio | (2.84) | |||
| Maximum Drawdown | 22.52 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 6.13 | |||
| Downside Variance | 14.29 | |||
| Semi Variance | 10.97 | |||
| Expected Short fall | (3.54) | |||
| Skewness | 0.0662 | |||
| Kurtosis | 1.26 |
SAB Biotherapeutics Backtested Returns
SAB Biotherapeutics appears to be moderately volatile, given 3 months investment horizon. SAB Biotherapeutics retains Efficiency (Sharpe Ratio) of 0.1, which indicates the company had a 0.1 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for SAB Biotherapeutics, which you can use to evaluate the volatility of the entity. Please review SAB Biotherapeutics' Market Risk Adjusted Performance of (2.83), standard deviation of 3.91, and Semi Deviation of 3.31 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, SAB Biotherapeutics holds a performance score of 8. The firm owns a Beta (Systematic Risk) of -0.16, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SAB Biotherapeutics are expected to decrease at a much lower rate. During the bear market, SAB Biotherapeutics is likely to outperform the market. Please check SAB Biotherapeutics' value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether SAB Biotherapeutics' current price history will revert.
Auto-correlation | 0.30 |
Below average predictability
SAB Biotherapeutics has below average predictability. Overlapping area represents the amount of predictability between SAB Biotherapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of SAB Biotherapeutics price movement. The serial correlation of 0.3 indicates that nearly 30.0% of current SAB Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.3 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
SAB Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, SAB Biotherapeutics reported net income of (34.11 Million). This is 109.99% lower than that of the Biotechnology sector and 148.69% lower than that of the Health Care industry. The net income for all United States stocks is 105.97% higher than that of the company.
SAB Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in net income category among its peers.
SAB Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SAB Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SAB Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
SAB Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in SAB Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of SAB Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing SAB Biotherapeutics' value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 11 K | Ubs Group Ag | 2025-06-30 | 10.7 K | Blackrock Inc | 2025-06-30 | 7 K | Advisor Group Holdings, Inc. | 2025-06-30 | 4.9 K | Sachetta Llc | 2025-06-30 | 4.1 K | Tower Research Capital Llc | 2025-06-30 | 726 | Mccormack Advisors International | 2025-06-30 | 217 | Gs Investment Inc | 2025-06-30 | 200 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 168 | Bvf Inc | 2025-06-30 | 917.8 K | Sessa Capital Im Lp | 2025-06-30 | 458.5 K |
SAB Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | 163.38 % | ||||
| Operating Margin | (376.57) % | ||||
| Current Valuation | 94.07 M | ||||
| Shares Outstanding | 47.61 M | ||||
| Shares Owned By Insiders | 12.36 % | ||||
| Shares Owned By Institutions | 69.92 % | ||||
| Number Of Shares Shorted | 1.56 M | ||||
| Price To Book | 1.20 X | ||||
| Price To Sales | 1,731 X | ||||
| Revenue | 1.32 M | ||||
| Gross Profit | (30.33 M) | ||||
| EBITDA | (28.99 M) | ||||
| Net Income | (34.11 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 4.67 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 3.48 X | ||||
| Cash Flow From Operations | (34.29 M) | ||||
| Short Ratio | 4.21 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Target Price | 9.38 | ||||
| Number Of Employees | 63 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 198.52 M | ||||
| Total Asset | 44.2 M | ||||
| Retained Earnings | (124.17 M) | ||||
| Working Capital | 15.81 M | ||||
| Net Asset | 44.2 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.